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Abstract
Background: Pre-eclampsia, a condition with raised blood pressure and proteinuria is associated with an increased
risk of maternal and offspring mortality and morbidity. Early identification of mothers at risk is needed to target
management.
Methods/design: We aim to systematically review the existing literature to identify prediction models for pre-eclampsia.
We have established the International Prediction of Pregnancy Complication Network (IPPIC), made up of 72 researchers
from 21 countries who have carried out relevant primary studies or have access to existing registry databases, and
collectively possess data from more than two million patients. We will use the individual participant data (IPD) from these
studies to externally validate these existing prediction models and summarise model performance across studies using
random-effects meta-analysis for any, late (after 34 weeks) and early (before 34 weeks) onset pre-eclampsia. If none of the
models perform well, we will recalibrate (update), or develop and validate new prediction models using the IPD. We will
assess the differential accuracy of the models in various settings and subgroups according to the risk status. We will also
validate or develop prediction models based on clinical characteristics only; clinical and biochemical markers; clinical and
ultrasound parameters; and clinical, biochemical and ultrasound tests.
Discussion: Numerous systematic reviews with aggregate data meta-analysis have evaluated various risk factors
separately or in combination for predicting pre-eclampsia, but these are affected by many limitations. Our large-scale
collaborative IPD approach encourages consensus towards well developed, and validated prognostic models, rather than
a number of competing non-validated ones. The large sample size from our IPD will also allow development and
validation of multivariable prediction model for the relatively rare outcome of early onset pre-eclampsia.
Trial registration: The project was registered on Prospero on the 27 November 2015 with ID: CRD42015029349.
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Background
Pre-eclampsia, a condition with raised blood pressure
and proteinuria in pregnancy, remains a leading cause of
maternal deaths worldwide [1], and is one of the
commonest causes of maternal admission to intensive
care in high-income countries [2]. It is associated with
increased perinatal mortality and foetal growth restric-
tion, and contributes to 10% of stillbirths and 15% of
preterm births [3, 4]. When pre-eclampsia occurs before
34 weeks’ gestation, known as early onset disease, it con-
siderably increases the risk of maternal complications,
with a 20-fold higher maternal mortality than late onset
disease [5–7].
Quantifying a woman’s risk of developing pre-
eclampsia during the course of the pregnancy is import-
ant to guide clinical decisions and monitoring strategies.
Pregnant women at high risk of pre-eclampsia require
close monitoring, and should be started on prophylactic
aspirin to reduce adverse outcomes [8]. Early com-
mencement of this has the potential for maximum
benefit [8]. Currently, clinical assessment for risk of pre-
eclampsia is mainly based on clinical history [9];
however, such risk-based predictions have shown limited
accuracy. In recent years, there has been intensive inter-
est in developing prediction models that incorporate
additional tests for biochemical and ultrasound markers
to improve predictive performance [10, 11]. Early onset
disease, occurring before 34 weeks’ gestation, is more
severe, and is considered to have a different pathophysi-
ology than the late onset disease. It is unlikely that a
single model will accurately predict both early and late
onset disease [12].
Clinical applicability of the tests and models predicting
pre-eclampsia based on the findings of aggregate meta-
analyses is limited. This is due to the observed hetero-
geneity in populations, in the combinations of predictors
and in outcome definitions (e.g. most published models
focussed on any pre-eclampsia rather than the much
more clinically severe early onset pre-eclampsia); and by
the lack of robust methods for aggregating data of
published models. Furthermore, prior to the use of
prediction models in clinical practice, there is a need to
successfully validate the model in multiple datasets ex-
ternal to the model development data. This often takes
many years to accomplish in a primary study.
Individual Participant Data (IPD) meta-analysis can
overcome many of the above limitations by accessing the
raw data of the individual participants. A large scale IPD
meta-analysis will enable us to predefine the desired
clinically relevant endpoints (e.g. timing of pre-eclampsia
onset). It will allow us to standardise the definitions of
predictors and outcomes, take into account the perform-
ance of many candidate prognostic variables, directly
handle missing data on both predictors and outcomes,
account for heterogeneity in baseline risks, and most
importantly, develop, validate and tailor the use of
the most accurate prediction models to the appropri-
ate population [13].
Methods/design
The IPPIC project will be undertaken using existing rec-
ommendations on prognostic research model develop-
ment and validation [14–16], and by adhering to recent
reporting guidelines for prediction models and IPD
meta-analysis [17, 18]. The project is registered on the
International prospective register of systematic reviews
(Prospero) with registration ID CRD42015029349 [19].
Objectives
We will develop, externally validate and update separate
prediction models for (i) early (< 34 weeks’ gestation), (ii)
late (≥ 34 weeks) and (iii) any onset pre-eclampsia.
Primary
1. To estimate the prognostic value of individual
clinical, biochemical and ultrasound markers for
predicting pre-eclampsia by IPD meta-analysis
2. To validate, and improve or tailor the performance
of existing models in relevant population groups, for
predicting early, late and any onset pre-eclampsia in
our IPD dataset based on:
– Clinical characteristics only
– Clinical and biochemical markers
– Clinical and ultrasound markers
– Clinical, ultrasound and biochemical markers
3. Using IPD meta-analysis, to develop and externally
validate (using internal-external cross-validation)
multivariable prediction models for early, late and
any onset pre-eclampsia in the following circum-
stances: where existing predictive strategies cannot
be adjusted for the target population, or where no
such models exist for the relevant pre-eclampsia
outcomes.
Secondary
4. To assess the differential performance of the existing
models in various predefined subgroups based on
population characteristics (unselected; selected) and
timing of model use (first trimester; second
trimester)
5. To study the effect on accuracy of adding novel
metabolic and micro-RNA based biomarkers to the
developed model based on clinical, ultrasound and
biochemical markers
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Literature search
We have previously undertaken the relevant systematic
reviews on clinical characteristics, biochemical and ultra-
sound markers for prediction of pre-eclampsia [20–34].
As a first step in the IPD meta-analysis, we will under-
take a systematic review of reviews, and additionally
search for primary studies not included in existing
reviews, as new research evidence may have appeared
since completion of our work. We will also update
our systematic review of prediction models for pre-
eclampsia [35] by searching the following databases:
MEDLINE, EMBASE, BIOSIS, LILACS, Pascal, Sci-
ence Citation Index, Cochrane Database of System-
atic Reviews (CDSR), Cochrane Central Register of
Controlled Trials (CENTRAL), National Institute of
Child and Human Development Data and Specimen
Hub (NICHD - DASH), Database of Abstracts of Re-
views of Effects (DARE) and Health Technology As-
sessment Database (HTA). Research reported in the
grey literature will be sought by searching a range of
relevant databases including the Inside Conferences,
Systems for Information in Grey Literature (SIGLE),
MotherChild Link Registry (http://www.linkregistry.org/
search.aspx), Dissertation Abstracts and Clinical Trials.gov.
Internet searches will also be carried out using specialist
search gateways, general search engines (such as Google:
http://www.google.co.uk/) and meta-search engines (such
as Copernic: http://www.copernic.com/). Language restric-
tions will not be applied to the electronic searches. We will
further ask primary authors to examine the included
study list to identify any studies, birth cohorts or
datasets that may have been missed. Collaborative
groups such as The Global Pregnancy CoLaboratory
(CoLab), Pre-eclampsia and Eclampsia Monitoring,
Prevention and Treatment (PRE-EMPT) and Global
Obstetrics Network (GONet) will also be approached
to identify primary studies, unpublished research and
birth cohorts [36–38].
Establishment of the IPPIC pre-eclampsia (International
Prediction of Pregnancy Complications) Network
We have established a collaborative network of investi-
gators (IPPIC) from research groups that have under-
taken studies on clinical characteristics, biochemical
and ultrasound markers in the prediction of early and
any onset pre-eclampsia. The network includes 72
researchers from 21 countries. A project-specific web-
site will be developed to improve visibility and commu-
nication. A memorandum of understanding will cover
the provision of data by the principal investigators of
the individual studies. We will agree on a timetable
and publication policy (policy of collaborative/group
authorship will be confirmed).
Eligibility criteria for relevant cohorts and studies
All identified primary studies (prospective and retro-
spective cohort studies, as well as cohorts nested within
randomised trials), and large birth and population based
cohorts which provide information to assess the accur-
acy of clinical, biochemical, and ultrasound predictors in
low, high or any risk women to predict early, late or any
pre-eclampsia and its complications will be eligible for
inclusion. Table 1 lists the characteristics of population,
predictors and outcome that will be included in the IPD
meta-analysis. The predictors will be clearly defined and
standardised, and will be chosen a priori for consider-
ation in the evaluation based on the most promising
predictor variables. [20–34] The primary outcomes are
early (< 34 weeks), late (≥ 34 weeks) and any pre-
eclampsia. Pre-eclampsia is defined as new onset hyper-
tension after 20 weeks gestation (BP greater than or
Table 1 Characteristics of population, predictors and outcome in the IPD meta-analysis on prediction of pre-eclampsia
Population Pregnant women
Predictors Maternal clinical characteristics at booking: Maternal characteristics: Age, BMI, height, weight, ethnicity, smoking, alcohol or substance
misuse; Medical history: pre-existing chronic kidney disease, heritable thrombophilias, autoimmune disease such as systemic lupus
erythematosus (SLE) and anti-phospholipid syndrome, type 1 and 2 diabetes and hypertensive diseases; Previous obstetric history:
parity, previous pre-eclampsia, GDM, pregnancy interval more than 10 years, family history of pre-eclampsia, family history of
cardiovascular disease, previous miscarriages, preterm birth, stillbirth or small for gestational age foetus; Current pregnancy: Multiple
pregnancy, mode of conception, early pregnancy bleeding, MAP, systolic and diastolic blood pressure, SES, new partner, diet or
exercise in pregnancy, urine dipstick, PCR, 24 h protein
Biochemical markers (first or second trimester): PAPP-A, sflt-1, PlGF, AFP, HCG, soluble endoglin, CRP, Hyper triglyceridaemia and PAI-1
Ultrasound markers (first or second trimester): CRL, AC, expected foetal weight centile, Uterine and umbilical artery Doppler (resistance
index, pulsatility index, unilateral or bilateral notching)
Outcomes Primary outcomes:
Early (<34 weeks), late (≥34 weeks) and any pre-eclampsia
Secondary outcomes:
Maternal complications: Eclampsia, HELLP syndrome, abruption, hepatic and renal failure, cortical blindness, pulmonary oedema,
postpartum haemorrhage, DIC, preterm delivery, admission to HDU, maternal death, caesarean section, GDM
Foetal and neonatal complications: Birth weight in Kg and centile, small for gestational age foetus, stillbirth, neonatal death, hypoxic
ischemic encephalopathy, respiratory distress syndrome, septicaemia, admission to neonatal unit
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equal to 140/90 mmHg) and new onset proteinuria of 2
or more on standard urinary dipstick tests and protein-
uria on spot urine PCR (protein creatinine ratio) test
greater than 30 mg/mmol or 24 h urine > 300 mg/24 h
[39]. The secondary outcome will be a composite ad-
verse maternal or foetal outcome.
Study selection, IPD collection and harmonisation
The minimum data to be collected for IPD meta-
analysis will be agreed at the first collaborators’ work-
shop by discussion with the collaborative group. We will
contact the authors of primary studies, and datasets to
obtain IPD, in any format, along with data dictionaries
or descriptions. The data will be obtained in an anon-
ymised format and stored in a secure data repository. All
variables recorded, even those not reported in the pub-
lished studies, will be considered for collection and for
planning subgroup analyses with sufficient statistical
power. We will build on existing efforts undertaken in
standardising the variables in the IPD meta-analysis pro-
jects on the prediction of pre-eclampsia, in specific sub-
groups of women, such as those with a previous history
of pre-eclampsia and for particular tests such as uterine
artery Doppler ultrasound in the second trimester.
Access to the existing IPD datasets will allow us to
rapidly set-up the database for the proposed project. Re-
searchers will supply data in the format most convenient
to them. The project team will take responsibility for
converting the data to the required format. There will be
flexibility in the format and method of transfer of pri-
mary data. All data supplied will be subjected to range
and consistency checks. Any missing data, obvious er-
rors, inconsistencies between variables or outlying values
will be queried and rectified through input from the ori-
ginal authors. At the time of submission of the protocol,
we have access to 74 IPD from 72 researchers. These
need further cleaning, quality assessment of the study,
data quality checks, and assessment of availability of
relevant data to evaluate their inclusion in the analysis.
The predictors of the original dataset will be matched
with the variables in the IPD, and where a direct match
is not available in the data, a new variable will be created
from other information contained within the original
dataset if possible, such as calculating BMI from weight
and height, or deriving mean pulsatility index by aver-
aging the left and right pulsatility index measurements.
Missing data over 10% for each variable, range checks
for variables with continuous measures, obvious errors,
inconsistencies between pre-identified variables that are
considered essential for the project or outlying values
will be queried and rectified with input from the original
authors. We will send two reminders to the original au-
thor for response to queries, after which a decision will
be taken by the project team on whether to exclude the
variable in question or the entire data itself.
We will use existing information within the provided
dataset where possible, to obtain information when not
available. For example, we shall use weight and height
data to calculate BMI. Where there is more than one
measurement, we will choose the first measurement. We
will consider predictors collected between 0 and
14 weeks as first trimester, > 14–28 weeks as second tri-
mester and >28 weeks as third trimester values. We will
also obtain information on treatment such as aspirin,
calcium and vitamin supplement use, which could influ-
ence the outcome. Although datasets may contain add-
itional variables, we will prioritise acquisition of those
that were included in the published prediction models to
validate and harmonise (e.g. transform to the same scale
or measurement unit if necessary).
Quality assessment
The risk of bias in individual studies or datasets will be
assessed by an early version of the Prediction study Risk
of Bias Assessment Tool (PROBAST) [40, 41]. Criteria
considered will include participant selection (adequate
description of data sources, details on recruitment),
predictors (appropriately defined, assessed blinded to
outcome, assessed in the same way for all participants),
and outcomes (appropriately defined and determined in
a similar way for all participants, predictors excluded
from the outcome definition, outcome determined with-
out knowledge of predictor information and appropriate
interval between assessment of predictor and outcome
determination). Applicability of the studies or datasets
will also be evaluated using the same tool above. We will
assess the extent to which the dataset provided is able to
answer the IPD meta-analysis question, in terms of the
population and outcomes of interest.
Data synthesis
In accordance with PRISMA-IPD, a flow diagram will be
drawn up showing the number of studies identified
through to the number of studies and participants in-
cluded in the analysis.
For all individual studies used to validate any of the
prediction models, study level characteristics will be
summarised and presented in Tables. A summary will
also be provided for the prediction models to be vali-
dated using the collected IPD.
Summarising the overall predictive accuracy of individual
predictors of pre-eclampsia
Meta-analysis will be used to summarise the prognostic
value of each clinical, biochemical, and ultrasound
marker, in relation to each of the binary outcomes of
early, late and any pre-eclampsia. The markers to be
Allotey et al. Diagnostic and Prognostic Research  (2017) 1:16 Page 4 of 13
evaluated are based on our systematic reviews in this
area. For each of the outcomes and markers of interest,
we will perform a two-stage IPD meta-analysis of the
prognostic effect, unadjusted and adjusted for particular
variables available across studies. The two-step approach
first involves fitting a logistic regression model for each
study, and then pooling the log odds ratios using a
conventional random effects meta-analysis. The random
effects model allows for heterogeneity between studies,
and will be estimated using REML. The 95% confidence
interval for the pooled effect will be derived using the
Hartung-Knapp approach. Heterogeneity will be sum-
marised using the I2 statistic (which provides the propor-
tion of total variability that is due to between-study
heterogeneity) and 95% prediction intervals. The
trend across multiple categories and across variables
that are continuous will be considered linear, al-
though suitable transformations (e.g. natural log) will
be considered if it improves model fit. Only single-
tons will be included in the analysis, and complete
case analysis will be employed.
Identifying relevant data for validation of existing models
Each model will be validated using IPD from studies that
contain all of the predictors in the model and the rele-
vant outcome (early, late or any pre-eclampsia). Ideally,
the time of measurement of the predictors and out-
comes should match for the setting in which the model
was developed, with generalisability to other measure-
ment times and outcomes assessed later. However, time
of predictor and outcome measurement may not always
be available, or may differ only slightly. Therefore, a
broad inclusion criterion will be used initially, and then
subgroups of datasets (e.g. those at low risk of bias) will
be considered that match the original model most cor-
rectly. Validation performance will be calculated for each
individual study separately, rather than using a com-
bined dataset containing all IPD. Model performance
will then be summarised across studies using random ef-
fects meta-analysis.
Missing data
Missing predictors If a predictor from a prediction
model is not present within an individual study (i.e. not
recorded for any of the participants in that study), this is
considered to be systematically missing. Though it may
be possible to impute values for the missing predictor
based on the IPD from other studies [42–44], for prac-
tical reasons, imputation will not be performed for sys-
tematically missing variables. Instead only the studies
that recorded all predictors for a particular model will
be used for validation of a particular prediction model.
If some participants are missing values for predictors
within an individual study, multiple imputations will be
used to recover data rather than dropping these partici-
pants from the analysis as in a complete case analysis.
The multiple imputations will be based on the individual
study, not the collection of all IPD studies. The imput-
ation process will be performed before any of the ana-
lysis takes place, therefore all relevant predictors (for all
prediction models to be validated) will be identified and
imputed for at the same time to avoid imputing values
for each different prediction model separately. This will
ensure a coherent set of imputed datasets, to be used
consistently in all analyses, regardless of the prediction
model being validated. The interest here is performance
statistics, which is sensitive to the type of imputation
model [45]. The imputation model will therefore include
other variables available within the dataset. Using the
rule of thumb that the number of imputed datasets (m)
should be at least equal to the percentage of incomplete
observations [46], m will be set equal to the largest per-
centage of incomplete observations in any of the studies,
and the same m will be used for all studies. For example,
if the largest percentage of incomplete observations in
any of the studies was 40%, 40 datasets will be imputed
for each study. For each validated model, performance
statistics (discussed later) will be averaged across imputa-
tions using Rubin’s rules to obtain one estimate and stand-
ard error (SE) for each performance statistic in each study
[47]. This will be done on the logit scale for the C-
statistic, as it is unlikely to be normally distributed on the
original scale. Within-imputation SEs can be obtained on
these transformed scale by applying the delta-method and
using the formulae given by Debray et al [48].
Predictors such as previous history of pre-eclampsia
may appear missing in some participants, solely because
the woman has not previously been pregnant. We will
therefore group women into three categories; Multiparous
with previous history of pre-eclampsia, Multiparous and
no previous history of pre-eclampsia and nulliparous and
treat these categories as separate predictors.
Missing outcomes If in an individual study some partici-
pants are missing details about whether the outcome oc-
curred or not, even after checking with the original study
authors, then these values will be imputed in the same
way as missing predictor values, using as many variables
as possible (including other available variables in addition
to model predictors) in the imputation model. Imputed
outcomes will be used in the analyses, rather than deleting
observations with missing outcomes [49].
Other considerations relating to the collected IPD for
external validation
Women with multiple pregnancies Patients may be in-
cluded in a study more than once if they had more than
one pregnancy. For the purpose of external validation,
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we will validate the model for each pregnancy of each
patient (i.e. keep all data) and consider each women’s preg-
nancy as a distinct observation. Though two or more preg-
nancy outcomes from the same women are likely to be
correlated, the number of multiple pregnancies is expected
to be very small relative to the total number of pregnan-
cies; further, external validation aims to ensure that a pre-
diction model is accurate for all applications, regardless of
whether it was applied to the same women previously.
Variables reported using multiples of the median
Some biomarkers and ultrasound markers have large vari-
ability due to factors such as gestational age and ethnicity,
and vary across laboratories in terms of their method of
measurement. Therefore, some researchers report them as
multiples of the median (MoM). The MoM of a predictor
value for a particular patient is calculated by a laboratory
using their own approach. Typically this is based on com-
paring the predictor value for that patient against the me-
dian value in that laboratory’s population, often after
adjustment for other factors (e.g. gestational age and eth-
nicity). Unfortunately, different laboratories may adjust for
different factors when calculating MoMs of a predictor,
and even if the same adjustment terms are used, the mag-
nitude of the adjustment effects (adjustment equation) is
not necessarily consistent across laboratories.
Several of the prediction models to be validated in-
clude biomarkers and/or ultrasound features reported as
MoMs, but not all IPD studies report the predictors as
MoMs. Such models will be validated only using those
studies that have reported MoMs for those predictors.
We will not calculate MoMs for IPD studies that do not
directly report the predictors as MoMs. This is because
we do not know what factors the other laboratories
would have adjusted for, how the adjusted medians
would be obtained, and what the laboratory set medians
would be. It would only be possible to calculate medians
for the patients within that study, rather than any larger
population, and thus would have not represented actual
practice. It was also not practical to contact the many la-
boratories represented in this IPD obtained.
Biomarkers may be measured using different assays
and platforms. As such, we will adjust for the biomarker
assay and platform in our analysis, and will consider
these as separate variables in our models.
IPD studies that do not report gestational age for
pre-eclampsia diagnosis If a study does not report the
gestational age when pre-eclampsia is diagnosed, there is
a possibility of the outcome occurring prior to bio-
marker measurement in some studies. If gestational age
at diagnosis of pre-eclampsia is not recorded, we will
use gestational age of delivery as a proxy for gestational
age of diagnosis.
External validation performance of existing models
If any of the studies for which IPD have been collected
were already used to develop a prediction model, it will
be excluded from the studies used to validate that par-
ticular model. This is because performance would be
over-optimistic in that dataset and will provide only ap-
parent or internal validation performance of the model
rather than external validation performance, which is of
interest to the IPD project.
We will report the predictive performance of a model in
terms of discrimination and calibration. Calibration refers
to how well the predictions from the model agree with the
observed outcomes, while discrimination relates to how
well a model can separate between women that develop
pre-eclampsia and those that do not [50, 51]. The per-
formance statistics are defined below, and will be calcu-
lated for each study separately, using (at least initially) all
relevant participants in each study. These will then be
summarised across studies using meta-analysis methods.
For each prediction model in each individual study,
the model equation will be applied to each participant in
the IPD to calculate the linear predictor value for that
participant (LPi, value of the linear combination of pre-
dictors in the model equation for individual i), as well as
the predicted probability of pre-eclampsia (using the in-
verse logit transformation of LPi).
For each prediction model, the distribution of LPi
values will be summarised for each study. The following
validation performance statistics will then be calculated:
C-statistic (discrimination)
The concordance statistic (C-statistic) gives the probabil-
ity of a randomly selected woman with pre-eclampsia
having a higher predicted probability than randomly se-
lected women without pre-eclampsia. The C-statistic is
equivalent to the area under the ROC curve, and will be
calculated (along with its SE) using non-parametric ROC
analysis in Stata using the ‘roctab’ command. It is likely
that the distribution of the C-statistic is not normal
since it is a proportion and therefore bounded by the
value 1. Therefore the logit scale will be used to pool
across imputations (as this is also the scale that will be
used later in the meta-analysis) [52]. The SE for logit(C-
statistic) can be calculated from the C-statistic and SE
for the C-statistic using the following formula [48]:
SE logit Cð Þð Þ ¼ SE Cð Þ
C 1−Cð Þ
Calibration-in-the-large
This measure indicates the extent that model predictions
are systematically too low or too high across the dataset.
The estimate of calibration-in-the large and its SE will be
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calculatedby fitting the calibrationmodel logit(pi) =α+β(LPi)
where α is the estimate of calibration-in-the-large, when
β = 1 (fitted using an offset term) and i refer to a
participant.
Calibration slope
The calibration slope indicates whether there is agree-
ment between observed outcomes and predictions across
the range of predicted risks. The calibration model,
logit(pi) = α + β(LPi) will be fitted and β is the estimated
calibration slope. Ideally, the calibration slope would be
equal or very close to 1 for good calibration. However, a
slope < 1 indicates overfitting of the model, whereas a
slope > 1 indicates underfitting.
Calibration plots
A graph showing the observed (O) and expected (E)
probabilities for groups of patients. Patients will be
grouped into deciles of the predicted probability, and O
versus E given for each group. A lowess smoother will
be applied to show the overall calibration slope, as calcu-
lated using all participants. As calibration plots cannot
be pooled across imputations, a calibration plot will be
drawn for each imputed dataset [53]. If the plots look
similar across imputations, the calibration plot from one
imputed dataset will be reported to illustrate this. If
different patterns are observed in different imputed
datasets, then a selection of plots may be presented.
Summarising model performance
Meta-analysis methods will be used to summarise a
model’s performance across all IPD used for external
validation. Random-effects will be used rather than
fixed-effect meta-analysis because it seems reasonable
that the performance of a model may differ across popu-
lations due to case-mix [48, 54]. Random-effects meta-
analysis will also allow us to quantify any heterogeneity
in performance across studies and predict model per-
formance in other similar settings using approximate
95% prediction intervals [55]. The random-effects model
for a performance measure can be written as
YkeNormal μk ; σk
2
 
μkeNormal μ; τ
2
 
where k refers to the study. The model assumes normal-
ity of the within-study and between-study performance
statistic. Based on the results of a simulation study [52],
the C-statistic will be pooled on the logit scale, as the
simulation study suggested this to be a more appropriate
scale for pooling C-statistics in a meta-analysis. The cali-
bration slope and calibration-in-the large will be pooled
on their original scale. Model performance will be
summarised for each statistic as the average and 95%
confidence interval for the average performance statis-
tic. Confidence intervals will be derived using the
Hartung-Knapp approach to account for uncertainty
in variance estimates [56]. Heterogeneity in model
performance across studies will be summarised using
the estimates of I2 statistic [57], and τ2, with approxi-
mate 95% prediction intervals calculated using the ap-
proach of Higgins et al. [58].
Model performance across studies will also be shown
graphically using forest plots for each performance stat-
istic and scatter plots to show measures of calibration
and discrimination in combination (to give an idea of
overall performance of the model).
Additional analyses relating to validation performance of
prediction models
Risk of bias
Performance of each prediction model (as described
above) will also be summarised according to the risk of
bias (using PROBAST) where there are enough studies
to do so; for example, summarising model performance
statistics for only the studies that are low risk of bias for
specified criteria to assess whether there is less hetero-
geneity in performance.
Generalisability of the model
Further analyses may include evaluating how widely the
model can be applied and how this affects the model
performance, each model could be applied to the follow-
ing settings:
 Different timing of the outcome (e.g. any pre-
eclampsia if the model was developed to predict
early pre-eclampsia)
 Different time of predictor measurement
Meta-regression If there are enough studies in the
analysis (10 or more studies), we will consider meta-
regression models as an exploratory analysis to investi-
gate if there are any differences in the performance
statistics due to the following pre-defined study-level
factors: outcome definition, study design, timing of the
outcome, timing of the predictor measurement, method
of measurement of predictor values, mean linear pre-
dictor, and variability of linear predictor (such as stand-
ard deviation).
Subgroup analyses
If a specific model performs reasonably well, say with a
C-statistic comparable or greater than that of the other
prediction models, and a calibration slope between 0.9
and 1.1 on average across validation studies, we may in-
terrogate the model performance further within specific
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subgroups. For example, in key patient groups such as
groups defined by age, parity and BMI. Meta-analysis
will be used to summarise subgroup performance across
studies where appropriate.
Publication and related biases
Publication bias is not expected because IPD are being
collected independent to the external validation per-
formance of each model. However, if there are 10 or
more studies for a particular model, then we will exam-
ine whether there are small-study effects (potential pub-
lication bias) on contour-enhanced funnel plots. If there
are small-study effects, the funnel plot will be asymmet-
ric, with larger studies showing different performance
estimates than smaller studies. Publication bias, IPD se-
lection bias and IPD availability bias may be underlying
reasons for any asymmetry. However, we will recognise
that heterogeneity may also be a genuine reason, for ex-
ample with smaller studies coming from populations or
cohorts with different case-mix variation.
Comparison of the performance of different models
If there is a subset of multiple studies that contain all
the predictors of two or more models that appear to
have good predictive performance upon validation
(based on the meta-analysis), then we will use this subset
of studies to directly compare the performance of these
models. Models will be ranked according to their dis-
crimination (largest C-statistic) and calibration measures
such as calibration slope. If there are enough studies
available, a bivariate meta-analysis of the C-statistic and
the calibration slope will be performed to jointly sum-
marise discrimination and calibration performance. The
results of the meta-analysis can be used to calculate the
probability of ‘good’ performance in future settings in
terms of both discrimination and calibration, where a
good C-statistic is defined as C-statistic ≥ 0.7 and good
calibration defined as a calibration slope between 0.9
and 1.1 [59].
Decision curve analysis is another method for evaluat-
ing and comparing prediction models (in addition to the
traditional validation measures of calibration and dis-
crimination). The net benefit of the model is plotted
against different probability thresholds to produce a de-
cision curve [60]. To obtain the curve, the prediction
model is evaluated at different probability thresholds
where the threshold is taken as a point above which a
patient would be treated, and below which a patient
would not be treated. The curve can then be compared
against the treat all and treat no-one strategies to see the
range of probabilities at which the model may be useful.
Decision curves can also be plotted for different models
on the same graph for comparison, and to help decide
which model offers the most benefit.
Decision curve analysis will be used to show the net
benefit of the pre-eclampsia prediction models being ex-
ternally validated, again using the subset of studies for
which a direct comparison of the most promising
models is possible. Decision curve analysis will be used
to compare them and see if one model offers greater net
benefit than the other. The model with the highest curve
(over a range of thresholds) is considered to have the
greatest net benefit.
Decision curve analysis will be run in Stata using the
dca command [61].
Updating (recalibrating) existing prediction models
Within each of the model categories (clinical, clinical
and biomarker, clinical and ultrasound, all three types of
markers), if a prediction model can be identified which
has good average discriminative performance (C-statistic
is comparable to, or greater than that of other models),
but is mis-calibrated (calibration slope not between 0.9
and 1.1) or has large heterogeneity in calibration
performance across different validation studies, we will
consider recalibration techniques such as using study-
specific intercepts, in an attempt to improve model per-
formance. If recalibration does not considerably improve
the performance of the model, we will consider develop-
ing and validating a new prediction model for that
model category.
Developing and validating new prediction models
If no existing model shows good performance even after
recalibration, and there is sufficient data to do so, we
will consider whether it is possible to develop and valid-
ate a new prediction model as necessary. This is
dependent on the amount of data available with com-
mon variables across studies and on the number of
events. Early onset pre-eclampsia is the rarest of the
three outcomes (0.5% of all pregnancies). As a rule of
thumb when developing a prediction model, we need at
least 10 events for each candidate predictor variable to
reduce the potential for large overfitting. If necessary, we
will limit the number of candidate predictors considered
to achieve this. However, we are likely to have an ad-
equate number of events per variable using IPD from
multiple studies.
Model development framework
If new prediction models are developed, a logistic regres-
sion framework will be used as pre-eclampsia is a binary
outcome (yes/no). A separate intercept will be used for
each study to allow for differences in the baseline risk
(e.g. different prevalence levels in different settings). We
will also fit a random intercept model and compare the
two approaches (stratified intercept versus average inter-
cept) in terms of model performance. We will also
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consider heterogeneity in the predictor effects to help
inform variable selection (a variable with a homogeneous
predictor effect across studies is preferred to a heteroge-
neous one). The same multiply imputed datasets as used
in the validation exercise will be used for model develop-
ment, with Rubin’s rules used to combine parameter
estimates across imputations as before. As correlated
outcomes per person may affect the standard errors of
model parameter estimates, we will check whether an
analysis that accounts for multiple pregnancies per
woman has any impact. This is unlikely, given the min-
imal proportion of multiple pregnancies for the same
woman.
Predictors to consider in model development
We will aim to identify a set of variables that are re-
corded in several of the studies (aiming for at least five
studies). If a variable is only recorded in one or two
studies, external validation in the other IPD studies will
also not be possible or will be very limited. We also want
a model that includes variables that are likely to be
routinely recorded in pregnant women.
Some variables are recorded using different scales,
such as the original predictor values and MoMs for bio-
markers and ultrasound variables, which are problematic
to convert to the same scale across studies. In this case,
we will look at which scale has been used most com-
monly in the IPD studies available, and use that scale, to
maximise the amount of data available for development
and validation.
Variable selection methods
Variable selection and deciding the functional form of
continuous variables (e.g. linear or non-linear function)
will take place within each cycle of the internal-external
cross-validation (detailed below). A multivariable frac-
tional polynomial (MFP) approach will be used, in which
fractional polynomial functions are tested for continuous
variables to determine the ‘best’ functional form of that
variable in the multivariable model (i.e. in the presence
of other variables rather than the best functional form
determined in a univariable model). Variables that are
well known to be predictors of pre-eclampsia will be
included in the prediction model, regardless of the sig-
nificance level, as agreed upon a consensus meeting. The
MFP approach begins with a full model (includes all po-
tential predictors being considered), and then backward
elimination is applied, removing the least significant
variable in each cycle of the procedure if the Wald test
p-value for that variable is greater than a specified value.
The criteria for elimination will be p > 0.157, which is
used as a proxy for selection based on all-subset Akaike’s
Information Criteria (AIC) [62]. If data within the stud-
ies have been imputed, the imputed datasets will be
stacked and a weighting applied to each dataset to per-
form variable selection [63]. This will be done using the
mfpmi command in Stata, using tests of Wald statistics
for nested hypotheses and the difference in Wald statis-
tics for non-nested hypotheses [64].
Internal-external cross-validation
An internal-external cross-validation (IECV) approach has
been proposed for model development and validation
when IPD are available from multiple studies [53, 65].
Using this approach, a model is developed using all but
one study which is reserved for model validation. The
model is then internally validated using the same data,
and using methods such as bootstrapping to calculate the
internal validation performance of the model. If necessary,
a shrinkage factor will be calculated and applied to
the regression coefficients. This model is then applied
to the omitted study and the validation performance
statistics calculated again. This process is repeated
multiple times, each time reserving a different study
for ‘external’ validation.
Overall model performance
Following IECV, there will be multiple statistics for each
validation performance statistic (one from each study).
These estimates will be summarised using random-
effects meta-analysis.
All analyses will be carried out using Stata MP 14.2.
Discussion
There has been an intense research effort to develop
clinically useful predictive tests for pre-eclampsia, which
remains a major contributor to maternal and perinatal
mortality and morbidity. Early identification of those at
increased risk of the disease would potentially allow for
targeted surveillance and intervention. It would also
mean that less intensive antenatal care is offered to
those at reduced risk. The current method of risk pre-
diction based on clinical history has limited predictive
accuracy, however it has been suggested that the
addition of biochemical and ultrasound markers may
improve the predictive performance. Given the large
number and diversity of the proposed tests, prediction
models have proliferated and become too numerous for
most researchers and/or healthcare providers to identify
the most clinically useful.
Systematic reviews on the performance of tests in pre-
eclampsia will need to take into account the variation in
population and test characteristics, treatment provided
and the timing of onset of pre-eclampsia. Numerous sys-
tematic reviews with aggregate data meta-analysis have
evaluated various risk factors separately or in combin-
ation for prediction of pre-eclampsia. These aggregate
data reviews are affected by the following limitations.
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Firstly, the aggregate meta-analyses are restricted by
the heterogeneity in the characteristics of the popula-
tion, timing of tests and cut offs, and the definitions of
outcome in published studies. This is especially prob-
lematic for the relatively rare but clinically important
outcome of early onset pre-eclampsia, which is often not
reported in individual studies. Heterogeneity in patient
selection can be reduced by IPD through strict inclusion
and exclusion criteria (i.e. removal and addition of par-
ticular patients in the dataset). Improved accuracy of
diagnosis and better definition of outcomes, particularly
gestational age at onset of pre-eclampsia, could be
accessed in individual patients by IPD meta-analysis, and
this is not possible when only aggregate data are
available.
Secondly, primary studies often report on only one test
or prediction model, despite available information on
more than one. Furthermore, any information on the
performance of multiple predictors in individual studies
is provided as mean values for the population. Hence, it
is difficult to undertake sensible evidence synthesis by
aggregate data meta-analyses, for evaluation of multiple
predictors. Furthermore, aggregate data meta-analyses of
multiple predictors have limited capabilities to develop
prediction models, yielding accurate estimates of abso-
lute risk for individual patients, particularly in the pres-
ence of between-study heterogeneity. By accessing the
individual data, IPD meta-analysis will provide a much
larger sample size to evaluate several candidate prognos-
tic factors in combination and subsequently develop
clinically relevant robust models. Access to IPD will also
enable recalibration of the prediction models in the
presence of between-study heterogeneity, and hence im-
prove the quality of individual risk predictions.
Thirdly, there is a need for appropriate methods of
meta-analysis to summarise the factor-outcome associa-
tions. Due to numerous problems of published primary
studies investigating factor-outcome associations, espe-
cially publication bias and selective reporting, aggregate
meta-analyses based on published results are notoriously
prone to bias, and show inconsistent and even contra-
dictory factor-outcome associations. The PROGRESS
group have shown multiple examples, across a broad
range of diseases, where aggregate data meta-analysis
has failed to identify clear conclusions about prognostic
factors [66] due to poor reporting. In IPD meta-analysis,
the association between future outcome and patient-
level characteristics and study level characteristics (set-
ting, timing, study design) can be assessed more reliably;
for example using a more consistent set of adjustment
factors and modelling biomarkers on their continuous
scale (rather than categorisation) [67].
Fourthly, prior to application of a model in clinical
practice, there is a need to evaluate its performance in
the population(s) in which it is intended for use. This re-
quires external validation of the model in a dataset dif-
ferent to that in which it was developed, requiring
additional sample size beyond model development, and
only possible with IPD (as aggregate data does not allow
predictions from a new model to be checked at the
patient-level). Lack of external validation is one of the
key reasons for the models not being adopted in clinical
practice. IPD meta-analysis offers an accepted way to
overcome this current lack of validation [68]. Further,
we will maximise the data for model development and
external validation by using an ‘internal-external cross
validation’ approach that accounts for multiple studies
by rotating them between model development and
validation. External validation performance (e.g. in
terms of calibration and discrimination) can then be
checked in each study, and summarised itself in a
meta-analysis [65, 69].
Fifthly, problems with aggregate data arise with differ-
ential treatment effects such as use of aspirin, by patient
characteristics. Obtaining individual participant data
(IPD) from these studies will facilitate a more reliable
meta-analysis, as treatment with aspirin will be available
at the individual-level. This will allow, for example, the
external validation performance of a model to be evalu-
ated across different groups of individuals defined by
their treatment, and considering the inclusion of treat-
ment as a predictor in the models.
An IPD meta-analysis framework with access to the
predictor-outcome data of individual patients, will allow
for the development and validation of multivariable pre-
diction models for early, late, and any pre-eclampsia.
Our prediction models will attempt to achieve this in
the following ways: use rigorous statistical methods to
develop the models and assess accuracy; undertake a
formal external validation within the IPD datasets; use
unambiguous definitions of predictors and reproducible
measurements using methods available in clinical prac-
tice; adjust and/or evaluate performance according to
current clinical management; involve patient groups in
model development and implementation; and produce
personalised risk scores that enable mothers and clini-
cians to make more informed decisions on management
aspects such as commencement of aspirin early in preg-
nancy and frequent monitoring in secondary and tertiary
care. The performance of the model will naturally be
limited by the strength of the predictive relationships be-
tween the measured variables and the outcome.
A good prediction model is one that yields accurate
(reliable) and consistent performance; validated in popu-
lations and datasets external to those used to develop
the model; widely applicable in practice; acceptable to
patients and ultimately improves clinical outcomes by
helping clinicians and patients make more informed
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decisions. External validation should ideally be done
across all clinical settings and relevant patient sub-
groups, in relation to the clinical context of defini-
tions for the start point (i.e. when predictions are
made from) and endpoint (e.g. early versus late onset
pre-eclampsia, or both).
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